Patents by Inventor Jinliang Yang

Jinliang Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250092091
    Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.
    Type: Application
    Filed: November 27, 2024
    Publication date: March 20, 2025
    Inventors: Subo Liao, Jun Yang, Jinliang Lv, Zongquan Liao, Hao Zhou, Jueyuan Gao, Tianpeng Xie, Quanli Yang, Lei Wang, Zejian Ding
  • Patent number: 12215173
    Abstract: The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: February 4, 2025
    Assignees: Humanwell Pharmaceutical US, Inc., Yichang Humanwell Pharmaceuticals Co. Ltd.
    Inventors: Subo Liao, Jun Yang, Jinliang Lv, Zongquan Liao, Hao Zhou, Jueyuan Gao, Tianpeng Xie, Quanli Yang, Lei Wang, Zejian Ding
  • Publication number: 20230233665
    Abstract: The present invention relates to the anti-SARS-CoV-2-infection protein and vaccine, and belongs to the field of medicine. Due to the lack of efficient drugs for SARS-CoV-2 infection prevention and treatment in the prior art, the present invention provides an anti-SARS-CoV-2-infection protein, which contains a domain that binds with the angiotensin-converting enzyme 2 (ACE2) receptor as contained in the SARS-CoV-2 S protein. One the other hand, the present invention also provides a vaccine for SARS-CoV-2 infection prevention and/or treatment, which comprises the anti-SARS-CoV-2-infection protein as well as the pharmaceutically acceptable excipient or auxiliary ingredient. The present invention mainly induces the production of antibodies in the body for immunoreaction and blocks the binding the SARS-CoV-2 S protein and the ACE2 receptor of the host cell, thus helping the host to fight against the corona virus infection.
    Type: Application
    Filed: September 18, 2020
    Publication date: July 27, 2023
    Inventors: Xiawei WEI, Guangwen LU, Wei WANG, Jinliang YANG, Li YANG, Jiong LI, Jingyun YANG, Yuquan WEI, Zhenling WANG, Zhiwei ZHAO, Guobo SHEN
  • Patent number: 8779233
    Abstract: The present invention relates to a method for determining an ear productivity trait in maize, which involves analyzing genomic DNA from a maize plant, germplasm, pollen, or seed for the presence of a molecular marker linked to a QTL associated with an ear productivity trait in maize. Also disclosed are methods of selecting a maize plant with a desired ear productivity trait; reliably and predictably introgressing an improved ear productivity trait into a maize line; and producing a maize line having a desired ear productivity trait. A kit for selecting a maize plant by marker assisted selection of a QTL associated with a desired ear productivity trait; an isolated nucleic acid comprising a QTL associated with an ear productivity trait in maize; and a transgenic plant comprising a recombinant nucleic acid genetically linked to a locus in maize, are also disclosed.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: July 15, 2014
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Patrick S. Schnable, Jinliang Yang, Ruth A. Swanson-Wagner, Dan Nettleton